<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing of selected parenteral beta-lactam antibiotics for adult patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing of selected parenteral beta-lactam antibiotics for adult patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing of selected parenteral beta-lactam antibiotics for adult patients</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">CrCl (mL/minute)</td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Frequency</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="4">Beta-lactamase inhibitor combinations</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Ampicillin-sulbactam (mild to moderate infections)</td> <td>≥30</td> <td>1.5 g</td> <td>Every 6 hours</td> </tr> <tr> <td>15 to 29</td> <td>1.5 g</td> <td>Every 12 hours</td> </tr> <tr> <td>5 to 14</td> <td>1.5 g</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>1.5 g</td> <td>Every 12 to 24 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>1.5 g</td> <td>Every 6 to 12 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Ampicillin-sulbactam (moderate to severe infections)</td> <td>≥30</td> <td>3 g</td> <td>Every 6 hours</td> </tr> <tr> <td>15 to 29</td> <td>3 g</td> <td>Every 12 hours</td> </tr> <tr> <td>5 to 14</td> <td>3 g</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>3 g</td> <td>Every 12 to 24 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>3 g</td> <td>Every 6 to 12 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="7">Ceftazidime-avibactam</td> <td>&gt;50</td> <td>2.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td>31 to 50</td> <td>1.25 g</td> <td>Every 8 hours</td> </tr> <tr> <td>16 to 30</td> <td>0.94 g</td> <td>Every 12 hours</td> </tr> <tr> <td>6 to 15</td> <td>0.94 g</td> <td>Every 24 hours</td> </tr> <tr> <td>≤5</td> <td>0.94 g</td> <td>Every 48 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>0.94 g</td> <td> <p>CrCl 6 to 15 mL/minute: Every 24 hours</p> <p>CrCl ≤5 mL/minute: Every 48 hours</p> Administer after iHD on dialysis days</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>[2]</sup> (based on preliminary data)</td> <td>1.25 g</td> <td>Every 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Ceftolozane-tazobactam (complicated UTI and intra-abdominal infections)</td> <td>&gt;50</td> <td>1.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td>30 to 50</td> <td>750 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>15 to 29</td> <td>375 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&lt;15</td> <td>Has not been studied</td> <td> </td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>750 mg once, followed by 150 mg</td> <td>Every 8 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>[3]</sup> (based on preliminary data)</td> <td>750 mg</td> <td>Every 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Ceftolozane-tazobactam (severe infections)<sup>[4,5]</sup></td> <td>&gt;50</td> <td>3 g</td> <td>Every 8 hours</td> </tr> <tr> <td>30 to 50</td> <td>1.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td>15 to 29</td> <td>750 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&lt;15</td> <td>Has not been studied</td> <td> </td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>750 mg once, followed by 375 mg</td> <td>Every 8 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>[3]</sup> (based on preliminary data)</td> <td>1.5 g</td> <td>Every 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Imipenem-cilastatin-relebactam</td> <td>≥90</td> <td>1.25 g</td> <td>Every 6 hours</td> </tr> <tr> <td>60 to 89</td> <td>1 g</td> <td>Every 6 hours</td> </tr> <tr> <td>30 to 59</td> <td>0.75 g</td> <td>Every 6 hours</td> </tr> <tr> <td>15 to 29</td> <td>0.5 g</td> <td>Every 6 hours</td> </tr> <tr class="divider_bottom"> <td>iHD<sup>*</sup></td> <td>0.5 g</td> <td>Every 6 hours; administer after iHD on dialysis days</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5"> <p>Meropenem-vaborbactam</p> <strong>NOTE:</strong> Use MDRD equation formula to estimate renal function (eGFR)</td> <td>≥50</td> <td>4 g</td> <td>Every 8 hours (infused over 3 hours)</td> </tr> <tr> <td>30 to 49</td> <td>2 g</td> <td>Every 8 hours (infused over 3 hours)</td> </tr> <tr> <td>15 to 29</td> <td>2 g</td> <td>Every 12 hours (infused over 3 hours)</td> </tr> <tr> <td>&lt;15</td> <td>1 g</td> <td>Every 12 hours (infused over 3 hours)</td> </tr> <tr class="divider_bottom"> <td>iHD<sup>*</sup></td> <td>1 g</td> <td>Every 12 hours (infused over 3 hours) administered after an iHD session</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Piperacillin-tazobactam (mild to moderate infections)</td> <td>&gt;40</td> <td>3.375 g</td> <td>Every 6 hours</td> </tr> <tr> <td>20 to 40</td> <td>2.25 g</td> <td>Every 6 hours</td> </tr> <tr> <td>&lt;20</td> <td>2.25 g</td> <td>Every 8 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>2.25 g</td> <td>Every 12 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>2.25 g</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Piperacillin-tazobactam (severe infections, including <em>Pseudomonas aeruginosa</em>)</td> <td>&gt;40</td> <td>4.5 g</td> <td>Every 6 hours</td> </tr> <tr> <td>20 to 40</td> <td>3.375 g</td> <td>Every 6 hours</td> </tr> <tr> <td>&lt;20</td> <td>2.25 g</td> <td>Every 6 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>2.25 g</td> <td>Every 8 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>3.375 g</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Sulbactam-durlobactam</td> <td>≥130 (augmented renal clearance)</td> <td>Sulbactam 1 g/durlobactam 1 g</td> <td>Every 4 hours</td> </tr> <tr> <td>45 to 129</td> <td>Sulbactam 1 g/durlobactam 1 g</td> <td>Every 6 hours</td> </tr> <tr> <td>30 to 44</td> <td>Sulbactam 1 g/durlobactam 1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>15 to 29</td> <td>Sulbactam 1 g/durlobactam 1 g</td> <td>Every 12 hours</td> </tr> <tr> <td>&lt;15</td> <td>Sulbactam 1 g/durlobactam 1 g</td> <td> <p>Every 12 hours for first 3 doses, then once daily</p> (NOTE: For patients whose CrCl declines to &lt;15 mL/minute after therapy has been initiated, administer once daily without loading dose)</td> </tr> <tr class="divider_bottom"> <td>iHD<sup>*</sup></td> <td>Sulbactam 1 g/durlobactam 1 g</td> <td> <p>Every 12 hours for first 3 doses, then once daily; administer after hemodialysis on dialysis days</p> (NOTE: For patients who require hemodialysis after therapy has been initiated, administer once daily without loading dose)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="4">Carbapenems</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Doripenem</td> <td>&gt;50</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>30 to 50</td> <td>250 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>11 to 29</td> <td>250 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>&lt;10</td> <td>Has not been studied</td> <td> </td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>250 to 500 mg</td> <td>Every 24 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup></td> <td>250 mg to 1 g</td> <td>Every 8 to 12 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="4">Ertapenem</td> <td>&gt;30</td> <td>1 g</td> <td>Every 24 hours</td> </tr> <tr> <td>≤30</td> <td>500 mg</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>500 mg</td> <td>Every 24 hours; administer after iHD on dialysis days</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[6]</sup> (based on preliminary data)</td> <td>1 g</td> <td>Every 24 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Imipenem-cilastatin (moderate infection)<sup>[7]</sup></td> <td>&gt;70 to 89</td> <td>500 mg</td> <td>Every 6 hours</td> </tr> <tr> <td>41 to 70</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>21 to 40</td> <td>250 mg</td> <td>Every 6 hours</td> </tr> <tr> <td>&lt;21</td> <td>250 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>250 mg</td> <td>Every 12 hours; administer after iHD on dialysis days</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>250 to 500 mg</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Imipenem-cilastatin (severe infection)<sup>[7]</sup></td> <td>&gt;70 to 89</td> <td>1 g</td> <td>Every 6<sup>Δ</sup> to 8 hours</td> </tr> <tr> <td>41 to 70</td> <td>500 mg</td> <td>Every 6 hours</td> </tr> <tr> <td>21 to 40</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&lt;21</td> <td>500 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>500 mg</td> <td>Every 12 hours; administer after iHD on dialysis days</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>500 mg</td> <td>Every 6 to 8 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Meropenem (meningitis, cystic fibrosis pulmonary exacerbation)</td> <td>&gt;50</td> <td>2 g</td> <td>Every 8 hours</td> </tr> <tr> <td>26 to 50</td> <td>2 g</td> <td>Every 12 hours</td> </tr> <tr> <td>10 to 25</td> <td>1 g</td> <td>Every 12 hours</td> </tr> <tr> <td>&lt;10</td> <td>1 g</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>1 g</td> <td>Every 24 hours; administer after iHD on dialysis days</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>500 mg or 1 g</td> <td>Every 8 to 12 hours</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="6">Meropenem (moderate to severe infection)<sup>◊</sup></td> <td>&gt;50</td> <td>1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>26 to 50</td> <td>1 g</td> <td>Every 12 hours</td> </tr> <tr> <td>10 to 25</td> <td>500 mg</td> <td>Every 12 hours</td> </tr> <tr> <td>&lt;10</td> <td>500 mg</td> <td>Every 24 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>500 mg</td> <td>Every 24 hours; administer after iHD on dialysis days</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>500 mg or 1 g</td> <td>Every 8 to 12 hours</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="4">Monobactam</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">Aztreonam (moderate infection)</td> <td>&gt;30</td> <td>1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>10 to 30</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>&lt;10</td> <td>250 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>1 g once, followed by 250 mg</td> <td>Every 8 to 12 hours</td> </tr> <tr class="divider_bottom"> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>2 g once, followed by 1 or 2 g</td> <td>1 g every 8 hours or 1 to 2 g every 12 hours</td> </tr> <tr> <td class="indent1" rowspan="5">Aztreonam (severe infection)</td> <td>&gt;30</td> <td>2 g</td> <td>Every 8 hours</td> </tr> <tr> <td>10 to 30</td> <td>1 g</td> <td>Every 8 hours</td> </tr> <tr> <td>&lt;10</td> <td>500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>iHD<sup>*</sup></td> <td>2 g once, followed by 500 mg</td> <td>Every 8 hours</td> </tr> <tr> <td>CRRT<sup>¶</sup><sup>[1]</sup></td> <td>2 g once, followed by 1 or 2 g</td> <td>1 g every 8 hours or 1 to 2 g every 12 hours</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>This table lists doses of selected beta-lactam antibiotics, with suggested dosing adjustments for renal impairment. The first dose listed for each agent represents the suggested dose for normal renal function. Renal function is evaluated based on estimated CrCl using the Cockcroft-Gault equation. A calculator for estimating CrCl based on the Cockcroft-Gault equation is available in UpToDate.</p>
<strong>NOTE:</strong> Doses listed for the combination beta-lactam/beta-lactamase inhibitors are expressed as the total of grams for both components.</div><div class="graphic_footnotes"><p>CrCl: creatinine clearance; CRRT: continuous renal replacement therapy; eGFR: estimated glomerular filtration rate; iHD: intermittent hemodialysis; MDRD: Modification of Diet in Renal Disease.</p>
<p>* Based on three times weekly dialysis sessions of 3 to 4 hours each; on dialysis days administer dose after dialysis. A loading dose may be warranted for some antibiotics depending on clinical scenario; refer to Lexicomp monograph for detail.</p>
<p>¶ General dose and interval range for different types of CRRT based on dialysate/ultrafiltration rate of 1 to 2 L/hour are listed. Specific dosing depends on CRRT method, flow rate, and filter type. For specific recommendations; refer to Lexicomp monograph included in UpToDate.</p>
<p>Δ An imipenem dose of 1 g given every 6 hours has been associated with an increased risk of seizures.<sup>[8]</sup></p>
◊ A lower dose is recommended for some skin/skin structure and urinary tract infections. Refer to Lexicomp monograph.</div><div class="graphic_reference">References:
<ol>
<li>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562.</li>
<li>Wenzler E, Bunnel KL, Belasdale SC, et al. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. Antimicrobial Agents Chemother 2017 [Epub ahead of print].</li>
<li>Bremmer DN, Nicolau DP, Burcham P, et al. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy 2016; 36:e30.</li>
<li>Munita JM, Aitken SL, Miller WR, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 2017 [Epub ahead of print].</li>
<li>Caston JJ, De la Torre A, Ruiz Camps I, et al. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2017; 61:e02136.</li>
<li>Eyler RF, Vilay AM, Nader AM, et al. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. Antimicrob Agents Chemother 2014; 58:1320.</li>
<li>Pham PA, Bartlett JG. Imipenem/cilastatin. In: Johns Hopkins Antibiotics Guide (<a href="https://www.hopkinsguides.com/hopkins" target="_blank">https://www.hopkinsguides.com/hopkins</a>), Unbound Medicine, 2017.</li>
<li>Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027.</li>
</ol>
<p class="extra_spacing_top">Courtesy of Stephen B Calderwood, MD and Alyssa R Letourneau, MD, with additional data from Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</p></div><div id="graphicVersion">Graphic 51241 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
